IndustryMay 2025
AstraZeneca Acquires EsoBiotec for $1B: Billion-Dollar Validation of Nanobody Technology
AstraZeneca completes the acquisition of EsoBiotec, a Belgian biotech whose core platform uses Engineered NanoBody Lentiviral (ENaBL) technology to program immune cells in vivo. The up-to-one-billion-dollar deal confirms premium valuations for VHH technology in the pharma landscape.
JFInnova Perspective
Big pharma is paying billions for nanobody platforms. JFInnova adds an extra layer: fully computational VHH design with AI validation, reducing discovery timelines from months to days.
References
1
AstraZeneca completes acquisition of EsoBiotec
AstraZeneca Press Release · 2025
AstraZeneca EsoBiotec nanobody acquisition VHH